reason report
tavr outperform push outlook higher less cautiou still
bottom line ew report adjust sale y/
ex fx beat consensu out-performance
almost entir driven thv transcathet heart valv
global sale exceed us consensu
respect quarter last ew
deliv global thv sale beat leav us less cautiou
low risk uptak least near term tough discern
exactli drove global thv sale beat whether earli adopt
low risk ahead approv broadli uplift overal
tavr volum base manag commentari suspect
latter particularli given fact ew rais global
thv sale guidanc midpoint --
-- impli underli global tavr sale
growth seen least sustain still maintain
mp rate need gain confid
out-performance thv sale growth acceler
result near-term bolu sustain next
month particularli given fact last quarterli
medacorp tavr survey point low-to-mid teen market
growth volum low-double-digit market growth
street number inevit move higher tomorrow
ew share -- undoubtedli deserv -- mind
also reset bar higher go forward continu
believ ew strong like unfalt market-lead
posit one higher-growth attract market within
med-tech share trade price-to-earnings estim
sens ew need sustain consist
beat rais quarter -- specif within thv and/or mitral --
warrant multipl expans
reiter mp pt price target appli
price-to-earnings multipl now-high ep estim pt
assum stabl multipl current ep also
now-high estim large-cap group averag
also think ew market-lead posit highli
valuat rel rest large-cap med-tech group mp
net debt total capit
price-to-earnings lt ep growth
medic suppli devic
ep
year price history/av daili volume mil ew
compani inform svb leerink llc research
revenu mm non-gaap dilut adjust ep
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
sale estim move higher boost tavr
out-performance less cautiou tavr outlook
sale estim y/i
previous ep also move higher
period larg driven now-high top-lin
think new estim reflect
bull-cas scenario base-cas given forward annual volum
growth project seen recent quarterli tavr survey tavr
survey link eu tavr survey link believ estim
incorpor bolu tavr adopt post-low risk data
mitral sale estim remain within
guidanc sale
takeaway call beyond thv out-performance
investor could also focu discontinu centera
believ actual highli strateg move given best-in-class
reput sapien increment invest centera would
requir bit lighter mitral quarter think investor
expect come -- ytd -- impli
meaning back half ramp hit compani sale
guidanc given mitral next leg growth ew stori
investor disproportion focus busi rel
overal import sale current ew receiv approv
clasp iif pivot trial pascal function mitral regurgit
patient initi enrol year-end ew also
expect initi pivot trial sapien transsept mitral valv
replac therapi year-end
rate edward lifesci nyse ew share market perform
price target edward current market leader tavr transcathet aortic
valv replac market intern continu believ tavr
repres one excit new med-tech market high-teen higher
project market compound-annual-growth-rate time-frame base estim sens
ramp less sick patient popul current intermedi risk potenti
low risk beyond might occur slower pace already-elev investor
expect continu believ intermedi risk indic repres massiv
increment market opportun estim intermedi risk doubl
address patient popul also believ ramp patient slower
saw inoper high risk given linger question around tavr durabl
longer term need seemingli intens market develop effort drive
referr particularli younger less sick portion intermedi risk patient popul
potenti increas surgeon pushback less sick patient popul
heart member ramp effort preserv surgic busi
ultim believ global tavr market reach new indic come
on-line low risk eventu asymptomat continu believ
low risk ramp like slower seen high risk intermedi risk
patient popul near-to-medium term ew still beat rais stori base
earli read intermedi risk adopt ramp think beat next
month may smaller tougher come last two
year particularli light competit launch addit steadier intermedi risk ramp
vs step function chang growth street seem expect share current trade
earn becom increasingli difficult argu meaning multipl
expans
price target appli price-to-earnings multipl now-high ep
estim pt assum stabl multipl current ep also now-
higher estim large-cap group averag also
think ew market-lead posit highli under-penetrated total address market
justifi premium valuat rel rest large-cap med-tech group mp
risk includ inflect point intermedi risk adopt ramp neg competit
clinic data and/or competit launch delay faster-than-expect low risk
asymptomat trial ramp earlier-than-expect cardiaq feasibl trial re-start
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
revenu
consensu incom statement item includ contributor factset
total transcathet mitral tricuspid
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
revenu
consensu incom statement item includ contributor factset
total transcathet mitral tricuspid therapi
consensu division revenu item includ contributor visibl alpha
consensu estim
compani report svb leerink estim factset visibl alpha
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
incom continu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
sg sale sale
impact
impact
impact
high end
high end
high end
high end
top
higher end
higher end
higher end
higher end
top end
sale tmtt
includ
tmtt
tmtt
tmtt
ew initi trial low-risk patient earli enrol trial began
random trail studi sapien low risk patient enrol
expect continu risk defin patient st score ew
see next step expans market intermedi risk posit trial
enrol year age limit also remov protocol
 oct trial tooker littl longer start-up phase ew continu expect earn call
site engag
 octob compani expect enrol complet year end
 decemb main studi enrol complet ct sub-studi continu enrol
 april ew receiv approv limit continu access protocol cap allow on-going
treatment select clinic site limit number low-risk patient sapien
approv cap continu access protocol cap program allow treatment complet trial
 juli ew still expect begin program
all-caus mortal stroke re-hospit time frame year post procedur
composit endpoint evalu non-inferior analysi base rel non-inferior margin
 februari ew expect result present
 decemb ew expect fda approv late
clinic trial prospect random control multi-cent studi patient
random receiv either transcathet aortic valv replac tavr edward
sapien thv clinic surveil patient stratifi whether abl
perform treadmil stress test patient posit stress test follow registri
collect data subsequ treatment mortal applic
ew plan enrol patient year older
 januari receiv fda approv patient across center begin enrol later
 octob trial continu enrol
 decemb analyst day patient enrol date ew expect complet enrol
sapien ultra new deliveri system expect better command system
new ultra system featur on-balloon deliveri system nextgener sheath technolog
sapien pulmon
 sapien pulmon valv expand indic pulmnic rvot conduit patch patient
 alterra adapt prestent pulmon patch patient expand treatabl popul
resili trial evalu
durabl aortic
resilia tissu subject
object observ trial determin time valv failur due valv deterior
requir re-intervent collect/investig earli potenti predictor valv durabl
calcif hemodynam deterior resilia tissu valv
-a decemb ew expect new ultra system featur on-balloon deliveri system nextgener
sheath technolog receiv ce mark end earli launch
 april ew conduct small clinic trial sapien ultra system supplement european regulatori
submiss unanticip start process reflect evolv european regulatori climat
manag expect complet enrol patient quarter receiv ce mark approv ultra system
second half
 juli enrol still on-going ew still expect secur ce mark
 octob ew still expect secur ce mark
 receiv ce mark novemb
 decemb compani expect approv late
 juli ew still expect fda approv late
 decemb ew expect fda approv end
 decemb pivot trial plane
end
multicent prospect non-random single-arm observ trial subject evalu year
post-impl two hundr fifti total subject fifteen investig site enrol
primari outcom measur time bioprosthet valv failur due valv deterior time frame year post-impl
-a januari ew recent paus enrol clinic trial perform design valid test featur
valv ew see posit result test clinic trial expect resum enrol paus
also postpon start ce mark trial
 juli ew expect resum enrol year
 octob ew decid includ number signific enhanc valv serv broader
group patient
 decemb expect enrol resum enhanc made
octob ew decid commerci valv system incorpor number enhanc ew
current ce mark expect
 decemb slimmer devic profil new transsapi deliveri system expect introduc
ew plan enrol multi-cent prospect single-arm non-random studi
-a plan enrol patient
ce mark studi subject complet document reduct sever mitral
regurgit mr improv minut walk test subject moder sever mr ew
aleadi ce mark product europ commerci launch on-go
 record commer sale europ
 present year follow-up data tct
cardioband repair studi transcathet repair mitral insuffici cardioband system
repair cardioband transcathet cardioband indic treatment
secondari function mitral regurgit fmr cardioband transcathet system deploy
beat heart transsept approach cardioband deploy along posterior
annulu mitral valv mv adjust trans-esophag guidanc beat heart
studi object test efficaci cardioband improv mr heart failur symptom
patient symptomat new york heart associ nyha class iii-iva sever mr post-
market set evalu safeti cardioband system post-market set
 pivot trial activ trial prospect random multicent trial patient
clinic signific function mitral regurgit random receiv either transcathet
mitral valv repair edward cardioband system plu guidelin direct medic therapi
gdmt gdmt alon patient seen follow-up visit discharg day month
annual year
complet enrol complet may ew actual enrol patient vs patient anticip
reduct sever mr day least one categori scale time frame day
on-go ew plan enrol patient
purpos studi assess safeti perform clinic outcom edward
pascal transcathet mitral valv repair tmvr multi-cent multi-n
prospect singl arm safeti perform clinic outcom studi
complet decemb publish posit data lancet present month result tct
ew plan enrol patient earli feasibl studi
 octob ew begun enrol ce mark trial expect expand trial multipl center
remaind year
 februari ew expect complet enrol
 decemb expect product launch
 decemb expect product launch
 februari ew track initi pascal trial
 juli ew continu treat patient feasibl studi
on-go ew plan enrol patient
repair treat broad
spectrum mitral regurgit
purpos studi assess safeti perform clinic outcom edward
pascal transcathet mitral valv repair tmvr multi-cent multi-n
prospect singl arm safeti perform clinic outcom studi
composit major advers event mae defin cardiovascular mortal stroke myocardi infarct new need renal
replac therapi sever bleed re-intervent studi devic relat complic day time frame
primari endpoint assess day
 octob ew receiv fda approv initi pascal pivot trial
on-go ew plan enrol patient
clasp iid prospect multicent random control pivot trial evalu safeti
effect transcathet mitral valv repair edward pascal transcathet mitral
valv repair system compar abbott mitraclip patient degen mitral regurgit
pascal inferior mitraclip respect proport patient major advers event mae primari
safeti endpoint composit major advers event mae time frame day
pascal inferior mitraclip respect proport patient mr sever reduct measur
echocardiographi use scale time frame month
cardioband activ enrol ce mark trial expand indic tricuspid patient target
ce mark approv
 earli feasibl studi set start
studi multi-cent prospect single-arm non-random studi design evalu
safeti perform edward cardioband tricuspid valv reconstruct system
 decemb ew plan initi pivot trial late
complet juli ew complet enrol ce mark trial cardioband tricuspid physician
 patient day earli readout present tct demonstr high procedur success good safeti
 decemb expect eu introduct late
 juli ew receiv ce mark
 februari ew receiv approv begin earli feasibl studi work activ center
 juli ew track begin earli feasibl studi may limit suppli
ew plan enrol patient
 januari ew increas estim enrol
cardioband transcathet cardioband market system approv
treatment secondari function mitral regurgit fmr ce grant septemb
cardioband annuloplasti band similar surgic annuloplasti howev deploy
beat heart transven approach ce mark studi subject
complet document signific reduct sever mr improv qualiti life
minnesota live heart failur questionnair mlhfq ney york heart associ nyha
minut walk test subject moder sever mr aim current studi
evalu cardioband annuloplasti system repair tricuspid regurgit
on-go ew plan enrol patient
spacer trial repair
use edward tricuspid
purpos studi assess safeti devic perform edward tricuspid
transcathet repair patient clinic signific symptomat tricuspid regurgit
high surgic risk standard tricuspid repair/replac studi multi-cent
intern prospect singl arm safeti studi enrol subject assess clinic follow-
month month year annual year post implant procedur
primari endpoint studi assess mortal cardiac treat cohort day compar literatur
deriv perform goal base high-risk surgic outcom tricuspid repair/replac
edward announc structur up-front invest harpoon pioneer beating-heart repair
degen mitral regurgit dmr exclus option acquir compani
dec edward announc acquisit harpoon medic inc million cash
potenti million pre-specifi milestone-driven payment next
 decemb ce mark expect year end earli
 april ew learn complic three treat earli clinic studi may influenc
time commerci launch
 februari ew expect european launch
 octob ew provid updat timelin
 juli ew expect european launch
